JP2017108751A5 - - Google Patents

Download PDF

Info

Publication number
JP2017108751A5
JP2017108751A5 JP2017023924A JP2017023924A JP2017108751A5 JP 2017108751 A5 JP2017108751 A5 JP 2017108751A5 JP 2017023924 A JP2017023924 A JP 2017023924A JP 2017023924 A JP2017023924 A JP 2017023924A JP 2017108751 A5 JP2017108751 A5 JP 2017108751A5
Authority
JP
Japan
Prior art keywords
arg
etv5
gene
exons
tmprss2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017023924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017108751A (ja
JP6404378B2 (ja
Filing date
Publication date
Priority claimed from US11/825,552 external-priority patent/US10041123B2/en
Application filed filed Critical
Publication of JP2017108751A publication Critical patent/JP2017108751A/ja
Publication of JP2017108751A5 publication Critical patent/JP2017108751A5/ja
Application granted granted Critical
Publication of JP6404378B2 publication Critical patent/JP6404378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017023924A 2007-07-06 2017-02-13 前立腺癌における再発性遺伝子融合 Expired - Fee Related JP6404378B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/825,552 US10041123B2 (en) 2005-09-12 2007-07-06 Recurrent gene fusions in prostate cancer
US11/825,552 2007-07-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015205414A Division JP2016019542A (ja) 2007-07-06 2015-10-19 前立腺癌における再発性遺伝子融合

Publications (3)

Publication Number Publication Date
JP2017108751A JP2017108751A (ja) 2017-06-22
JP2017108751A5 true JP2017108751A5 (enExample) 2017-11-30
JP6404378B2 JP6404378B2 (ja) 2018-10-10

Family

ID=40210565

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010515276A Expired - Fee Related JP5529732B2 (ja) 2007-07-06 2008-07-03 前立腺癌における再発性遺伝子融合
JP2014016532A Expired - Fee Related JP6035634B2 (ja) 2007-07-06 2014-01-31 前立腺癌における再発性遺伝子融合
JP2015205414A Withdrawn JP2016019542A (ja) 2007-07-06 2015-10-19 前立腺癌における再発性遺伝子融合
JP2017023924A Expired - Fee Related JP6404378B2 (ja) 2007-07-06 2017-02-13 前立腺癌における再発性遺伝子融合

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2010515276A Expired - Fee Related JP5529732B2 (ja) 2007-07-06 2008-07-03 前立腺癌における再発性遺伝子融合
JP2014016532A Expired - Fee Related JP6035634B2 (ja) 2007-07-06 2014-01-31 前立腺癌における再発性遺伝子融合
JP2015205414A Withdrawn JP2016019542A (ja) 2007-07-06 2015-10-19 前立腺癌における再発性遺伝子融合

Country Status (6)

Country Link
EP (3) EP2604701B1 (enExample)
JP (4) JP5529732B2 (enExample)
AU (1) AU2008275304B2 (enExample)
CA (2) CA2692441C (enExample)
WO (1) WO2009009432A2 (enExample)
ZA (1) ZA201000128B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1934363B1 (en) 2005-09-12 2013-03-20 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8273539B2 (en) 2006-09-25 2012-09-25 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
ES2376509T3 (es) 2007-07-06 2012-03-14 The Regents Of The University Of Michigan Reordenamientos de genes mipol 1-etv1.
CA2692441C (en) * 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc SYSTEMS AND METHODS FOR THE EXPRESSION-BASED DISTINCTION OF DIFFERENT CLINICAL ILLICIT STADIAS IN PROSTATE CANCER
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
JP5800817B2 (ja) * 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
JP6044935B2 (ja) 2013-03-11 2016-12-14 学校法人日本大学 新規piポリアミド
EP2971101A2 (en) 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers
EP2975078A1 (en) 2014-08-14 2016-01-20 Omya International AG Surface-treated fillers for breathable films
WO2017061128A1 (ja) 2015-10-08 2017-04-13 凸版印刷株式会社 ピロールイミダゾール含有ポリアミドを用いた標的二本鎖核酸分子の濃縮方法およびキット
CN110506127B (zh) 2016-08-24 2024-01-12 维拉科特Sd公司 基因组标签预测前列腺癌患者对术后放射疗法应答性的用途
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
EP4428157A3 (en) 2017-08-04 2024-12-11 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
CN114634913A (zh) * 2022-02-27 2022-06-17 复旦大学 肿瘤硬脑膜转移模型的构建方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4323546A (en) 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0232967B1 (en) 1986-01-10 1993-04-28 Amoco Corporation Competitive homogeneous assay
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US4968103A (en) 1988-07-22 1990-11-06 Photofinish Cosmetics Inc. Method of making a brush
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
DE69034177T2 (de) 1989-07-11 2005-10-27 Gen-Probe Inc., San Diego Verfahren zur Amplifikation von Nukleinsäuresequenzen
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
EP0552108B1 (en) 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
EP0672131B1 (en) 1992-10-30 2003-12-17 The General Hospital Corporation A novel cell cycle control protein
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
WO1994018987A1 (fr) 1993-02-19 1994-09-01 Nippon Shinyaku Co., Ltd. Composition medicinale renfermant un copolymere d'acide nucleique
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
DE69534166T2 (de) 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
CA2249742A1 (en) 1996-03-15 1997-09-18 Steven G. Reed Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
DE69738687D1 (de) 1996-04-12 2008-06-26 Phri Properties Inc Sonden, kits und assays
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
BR9808881A (pt) 1997-02-25 2001-09-11 Corixa Corp Compostos para imunoterapia de câncer de próstata e métodos para seu uso
EP0965034B1 (en) 1997-03-07 2007-05-30 Clare Chemical Research, Inc. Fluorometric detection using visible light
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US7008765B1 (en) 1997-04-10 2006-03-07 The Johns Hopkins University PCA3, PCA3 genes, and methods of use
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
NZ500657A (en) 1997-07-11 2002-11-26 Introgene B Interleukin-3 gene therapy for cancer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
EP1092047B1 (en) 1998-07-02 2009-08-26 Gen-Probe Incorporated Molecular torches
MXPA01001727A (es) 1998-08-14 2001-11-27 Aventis Pharm Prod Inc Formulaciones de adenovirus para terapia genetica.
IL141500A0 (en) 1998-08-27 2002-03-10 Aventis Pharma Sa Targeted adenovirus vectors for delivery of heterologous genes
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6541205B1 (en) 1999-05-24 2003-04-01 Tosoh Corporation Method for assaying nucleic acid
AU2001268513A1 (en) 2000-06-17 2002-01-02 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
JP4336198B2 (ja) 2001-09-06 2009-09-30 アトナーゲン アクチエンゲゼルシャフト 細胞の選択、および/または定性および/または定量検出のための方法および診断キット
JP2005517450A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸(siNA)を用いるRNA干渉媒介性標的発見および標的評価
US8679789B2 (en) 2003-05-01 2014-03-25 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch
WO2005038054A1 (en) 2003-10-20 2005-04-28 Zicai Liang METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
GB0327726D0 (en) 2003-11-28 2003-12-31 Isis Innovation Method
ATE500344T1 (de) 2004-08-27 2011-03-15 Gen Probe Inc Einfach-primernukleinsäuren-erweiterungsverfahr n
EP1934363B1 (en) * 2005-09-12 2013-03-20 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2692441C (en) * 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer

Similar Documents

Publication Publication Date Title
JP2017108751A5 (enExample)
JP2019196400A5 (enExample)
JP5861244B2 (ja) 新規ros1融合体の検出法
JP2010508855A5 (enExample)
JP2010259438A5 (enExample)
JP2009507492A5 (enExample)
JP2010532663A5 (enExample)
WO2011034906A4 (en) Recurrent gene fusions in prostate cancer
WO2014047285A1 (en) Identifying taxane sensitivity in prostate cancer patients
JP2015531590A5 (enExample)
WO2013141266A1 (ja) 新規ret融合体の検出法
JP2019023645A5 (enExample)
JP6531312B2 (ja) Bcr−abl阻害剤耐性関連変異の検出方法及びこれを用いたbcr−abl阻害剤耐性を予測するためのデータ取得方法
RU2016144177A (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
CN105543408B (zh) 冠心病早期诊断标志物
JP2008509673A5 (enExample)
JP2013536442A5 (enExample)
CN106795550A (zh) 与前列腺癌有关的基因组重排和使用所述基因组重排的方法
CN102439174B (zh) 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法
JP2015524656A (ja) Cdk阻害剤と関連するバイオマーカー
CN102234681A (zh) 一种检测基因融合的方法
Okuyama Kishima et al. Genetic polymorphism and expression of CXCR4 in breast cancer
JP2013503644A5 (enExample)
ES2906203T3 (es) Variante de CIP2A novedosa y usos de la misma
Guo et al. Detection of circulating tumor cells by reverse transcription‑quantitative polymerase chain reaction and magnetic activated cell sorting in the peripheral blood of patients with hepatocellular carcinoma